A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!

Itchy skin commonly occurs with polycythemia vera. Treatment may include medications, UV therapy, and lifestyle changes, such as applying moisturizer and avoiding triggers. One of the most common ...

the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and polycythemia vera must be excluded. The present case and others in the literature indicate that the ...

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has ...

Vanda Pharmaceuticals Inc.’s VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor, has been awarded orphan drug designation by the FDA for the treatment of polycythemia vera.